Tumor News and Research

RSS

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

Nano-sized EVs play role in cancer growth and survival

The recent discovery of circulating "nano-sized extracellular vesicles" (EVs) carrying proteins and nucleic acids derived from brain tumors may lead to exciting new avenues for brain cancer diagnosis, monitoring, and treatment, according to a special article in the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

9 Apr 2013

Study: Chicken-killing virus is a promising treatment for prostate cancer

A study at the Virginia-Maryland Regional College of Veterinary Medicine has identified a chicken-killing virus as a promising treatment for prostate cancer in humans.

9 Apr 2013

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies.

9 Apr 2013

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor, fuels a wide variety of cancers-including a highly malignant brain cancer known as glioblastoma.

9 Apr 2013

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

The mammalian target of rapamycin, mTOR is a central integrator of the cell that coordinates growth factor receptor signaling with energy and nutrient status to control a wide array of activities, including the regulation of cellular proliferation and survival.

9 Apr 2013

Scientists succeed to control cells' behavior using light

Scientists at Washington University School of Medicine in St. Louis have shown they can coax cells to move toward a beam of light. The feat is a first step toward manipulating cells to control insulin secretion or heart rate using light.

9 Apr 2013

American Cancer Society announces new research, training grants for fiscal year 2013

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013.

9 Apr 2013

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors.

9 Apr 2013

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream.

9 Apr 2013

Researchers discover that fruit fly mutation holds clues for treating motor neuron diseases

A team of researchers, led by Marc Freeman, PhD, an early career scientist with the Howard Hughes Medical Institute and associate professor of neurobiology at the University of Massachusetts Medical School have discovered a gene in the fruit fly Drosophila melanogaster that, when mutant, blocks the self-destruction of damaged axons, which could hold clues to treating motor neuron diseases, such as amyotrophic lateral sclerosis.

9 Apr 2013

New drug combination shows anti-cancer activity in patients with solid tumors and germline mutation

A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013

Study evaluates efficacy of drug combinations in treating colorectal cancer

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis.

8 Apr 2013

GE Healthcare releases next-generation sequencing assay for use in clinical trials

GE Healthcare announced today that Clarient Diagnostic Services, Inc., a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical trials.

8 Apr 2013

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium of the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Nektar Therapeutics today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research Annual Meeting.

8 Apr 2013

Physician-researcher to lead pediatric Dream Team to create new treatments for childhood cancers

A physician-researcher from The Children's Hospital of Philadelphia will lead the first-ever pediatric "Dream Team" solely focused on creating new treatments for the most challenging childhood cancers.

8 Apr 2013

Tumor News and Research

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Nano-sized EVs play role in cancer growth and survival

Study: Chicken-killing virus is a promising treatment for prostate cancer

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

Scientists succeed to control cells' behavior using light

American Cancer Society announces new research, training grants for fiscal year 2013

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Researchers discover that fruit fly mutation holds clues for treating motor neuron diseases

New drug combination shows anti-cancer activity in patients with solid tumors and germline mutation

Study evaluates efficacy of drug combinations in treating colorectal cancer

GE Healthcare releases next-generation sequencing assay for use in clinical trials

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Physician-researcher to lead pediatric Dream Team to create new treatments for childhood cancers

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News